Practice Economics

Medicare at 50: High-price therapeutics put Medicare at a crossroad


 

References

When it comes to costly medications and treatments, Medicare’s fee-for-service design isn’t helping either.

Dr. Jeffery Ward

Dr. Jeffery Ward

“We have a payment system that works through a third party payer, so the person who needs the care is not usually the person who is paying for the care,” said Dr. Jeffery Ward, an oncologist who serves on the clinical practice committee of the American Society of Clinical Oncology. “Prices and the fees are set based on what you do. I don’t get paid better for doing a good job than I would get for doing a cruddy job. [Once,] that served medicine and Medicare well, but now we have a health care crisis.”

Dr. Ward added that incentives are misaligned in a manner that rewards doctors for choosing more expensive drugs and procedures for their patients.

As oncologists, “we are going to have get over our addiction to [being compensated on the] margin on drugs,” Dr. Ward said. “We’re going to have to be able to develop a system and have faith in a system that will pay us fairly for what we do instead of paying us based on what drugs we choose.”

Dr. Steven Allen

Dr. Steven Allen

However, Dr. Steven Allen, who chairs the American Society of Hematology committee on practice, said that he doesn’t believe that is a key issue.

“I think you are really only referring to a very small percentage of physicians,” Dr. Allen said. “I think the vast majority of physicians do what’s right for their patients. ... They will choose the best drug for their patients regardless of the reimbursement the physician may receive given that drug.”

Dr. Ward said that to address the need to cover these potent, high-cost treatments, “I think what Medicare is going to have to do at its 50th birthday is figure out how to begin to reward physicians for doing the right thing and for providing quality care instead of simply paying for quantity.”

The federal government is moving in that direction. In January, Health and Human Services Secretary Sylvia Burwell announced a new goal for Medicare: Fifty percent of all payments should be value based by 2018 (N. Engl. J. Med. 2015;372:897-9 [doi 10.1056.NEJMp1500445]). But what exactly does value mean? While that point is debated on a broad scale, one thing that is obvious is that it will require a culture shift on a many levels.

gtwachtman@frontlinemedcom.com

Pages

Recommended Reading

Doctors hail House vote to repeal, replace SGR
MDedge Hematology and Oncology
Senate recesses without addressing SGR repeal bill
MDedge Hematology and Oncology
Commonwealth Fund: ACA’s medical loss ratio rule saves $5 billion
MDedge Hematology and Oncology
Supreme Court won’t hear IPAB challenge
MDedge Hematology and Oncology
New team of experts to guide Precision Medicine Initiative
MDedge Hematology and Oncology
Supreme Court: Docs cannot sue over low Medicaid payments
MDedge Hematology and Oncology
Vaccine pioneer begins reign as acting director of the National Cancer Institute
MDedge Hematology and Oncology
SGR cuts pay by 21%; CMS to hold checks for 2 weeks
MDedge Hematology and Oncology
Uninsured made coverage gains from 2013 to 2014
MDedge Hematology and Oncology
Medicare is stingy in first year of doctor bonuses
MDedge Hematology and Oncology